AstraZeneca plc., is a global, innovation-driven biopharma major formed through the merger of Swedish Astra AB and British Zeneca Group Plc in 1999.
- In Dec 2015, AstraZeneca acquired 55% ownership in Acerta Pharma B.V, for $4 Billion with an option to acquire remaining 45% ownership in Acerta for up to $3 Billion. Acerta Pharma is developing Calquence, a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK).
- In Oct 2013, AstraZeneca’s subsidiary MedImmune acquired 100% of Spirogen for $200 million in cash and deferred consideration of up to $240 Mn USD.
- In Aug 2013, MedImmune, AstraZeneca’s global biologics research and development arm, acquired Amplimmune in $500 Mn USD.
- In Jun 2012, AstraZeneca acquired Ardea Biosciences, a biotechnology company, for $1.26 billion USD and make it its wholly owned subsidiary.
- In Apr 2007, AstraZeneca acquired MedImmune in $15.6 billion USD and make it its wholly owned subsidiary.
- In May 2006, Cambridge Antibody Technology, a biotechnology company developing Ab therapeutics was acquired by AstraZeneca in $1.32 billion USD.
- In Dec 2005, AstraZeneca acquired KuDOS Pharmaceuticals, an oncology driven UK biotechnology company, in $121 Mn USD.
Page 1 of 3
